Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24282932 | 0.88 | GPR119 (0.45) | DDB1CRBNMAPK1NAMPTGPR119 | |
| SCHEMBL29609272 | 0.88 | GPR119 (0.45) | DDB1CRBNMAPK1NAMPTGPR119 | |
| SCHEMBL30529412 | 0.86 | MAPK1 (0.43) | DDB1CRBNMAPK1NAMPTGPR119 | |
| SCHEMBL21940705 | 0.84 | NAMPT (0.43) | DDB1CRBNMAPK1NAMPTGPR119 | |
| SCHEMBL25398481 | 0.83 | ESR2 (0.39) | DDB1CRBNGPR119RORC | |
| SCHEMBL29609474 | 0.83 | ESR2 (0.39) | DDB1CRBNGPR119RORC | |
| SCHEMBL25403345 | 0.81 | DDB1 (0.42) | DDB1CRBNGPR119RORC | |
| SCHEMBL29609259 | 0.81 | DDB1 (0.42) | DDB1CRBNGPR119RORC | |
| SCHEMBL26284403 | 0.81 | GPR119 (0.39) | DDB1CRBNMAPK1NAMPTGPR119 | |
| SCHEMBL21940706 | 0.79 | NAMPT (0.40) | DDB1CRBNMAPK1NAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | DDB1 1135/4885CRBN 232/4885MAPK1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.